Figure 2From: Cost-utility analysis of adjuvant goserelin (Zoladex) and adjuvant chemotherapy in premenopausal women with breast cancer Survival curves of adjuvant goserelin and adjuvant chemotherapy for premenopausal breast cancer patients with extrapolation of 50 years.Back to article page